Downregulation of long noncoding RNA TP73-AS1 expression confers resistance to temozolomide in human glioblastoma cells

References

• Wilson, T. A.; Karajannis, M. A.; Harter, D. H. Glioblastoma Multiforme: State of the Art and Future Therapeutics. Surg. Neurol. Int. 2014, 5, 64. DOI: 10.4103/2152-7806.132138.
   PubMedGoogle Scholar
• Louis, D. N.; Perry, A.; Reifenberger, G.; von Deimling, A.; Figarella-Branger, D.; Cavenee, W. K.; Ohgaki, H.; Wiestler, O. D.; Kleihues, P.; Ellison, D. W. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A Summary. Acta Neuropathol. 2016, 131, 803–820. DOI: 10.1007/s00401-016-1545-1.
   PubMed Web of Science ®Google Scholar
• Brain Tumor Registry of Japan (2005–2008). Neurol Med Chir (Tokyo) 2017, 57, 9–102.
   PubMedGoogle Scholar
• Zhang, J.; Stevens, M. F.; Bradshaw, T. D. Temozolomide: Mechanisms of Action, Repair and Resistance. Curr. Mol. Pharmacol. 2012, 5, 102–114. DOI: 10.2174/1874467211205010102.
   PubMedGoogle Scholar
• Lee, S. Y. Temozolomide Resistance in Glioblastoma Multiforme. Genes Dis. 2016, 3, 198–210. DOI: 10.1016/j.gendis.2016.04.007.
   PubMed Web of Science ®Google Scholar
• Jiapaer, S.; Furuta, T.; Tanaka, S.; Kitabayashi, T.; Nakada, M. Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma. Neurol. Med. Chir (Tokyo) 2018, 58, 405–421. DOI: 10.2176/nmc.ra.2018-0141.
   PubMed Web of Science ®Google Scholar
• Singh, N.; Miner, A.; Hennis, L.; Mittal, S. Mechanisms of Temozolomide Resistance in Glioblastoma - a Comprehensive Review. Cancer Drug Resist. 2021, 4, 17–43. DOI: 10.20517/cdr.2020.79.
   PubMedGoogle Scholar
• Trejo-Solís, C.; Serrano-Garcia, N.; Escamilla-Ramírez, Á.; Castillo-Rodríguez, R. A.; Jimenez-Farfan, D.; Palencia, G.; Calvillo, M.; Alvarez-Lemus, M. A.; Flores-Nájera, A.; Cruz-Salgado, A.; Sotelo, J. Autophagic and Apoptotic Pathways as Targets for Chemotherapy in Glioblastoma. Int. J. Mol. Sci. 2018, 19, 3773.
   PubMed Web of Science ®Google Scholar
• Wang, K. C.; Chang, H. Y. Molecular Mechanisms of Long Noncoding RNAs. Mol. Cell. 2011, 43, 904–914. DOI: 10.1016/j.molcel.2011.08.018.
   PubMed Web of Science ®Google Scholar
• Schmitt, A. M.; Chang, H. Y. Long Noncoding RNAs in Cancer Pathways. Cancer Cell. 2016, 29, 452–463. DOI: 10.1016/j.ccell.2016.03.010.
   PubMed Web of Science ®Google Scholar
• Ahmed, S. P.; Castresana, J. S.; Shahi, M. H. Glioblastoma and MiRNAs. Cancers (Basel) 2021, 13, 1581. DOI: 10.3390/cancers13071581.
   PubMed Web of Science ®Google Scholar
• Mahinfar, P.; Baradaran, B.; Davoudian, S.; Vahidian, F.; Cho, W. C.; Mansoori, B. Long Non-Coding RNAs in Multidrug Resistance of Glioblastoma. Genes (Basel) 2021, 12, 455. DOI: 10.3390/genes12030455.
   PubMed Web of Science ®Google Scholar
• Yuan, E.; Liu, K.; Lee, J.; Tsung, K.; Chow, F.; Attenello, F. J. Modulating Glioblastoma Chemotherapy Response: Evaluating Long Non-Coding RNA Effects on DNA Damage Response, Glioma Stem Cell Function, and Hypoxic Processes. Neurooncol. Adv. 2022, 4, vdac119.
   PubMedGoogle Scholar
• Inada, M.; Shindo, M.; Kobayashi, K.; Sato, A.; Yamamoto, Y.; Akasaki, Y.; Ichimura, K.; Tanuma, S. I. Anticancer Effects of a Non-Narcotic Opium Alkaloid Medicine, Papaverine, in Human Glioblastoma Cells. PLoS One. 2019, 14, e0216358. DOI: 10.1371/journal.pone.0216358.
   PubMed Web of Science ®Google Scholar
• Kurasaka, C.; Ogino, Y.; Sato, A. Molecular Mechanisms and Tumor Biological Aspects of 5-Fluorouracil Resistance in HCT116 Human Colorectal Cancer Cells. Int J Mol Sci 2021, 22, 2916.
   PubMed Web of Science ®Google Scholar
• Sato, A.; Nakama, K.; Watanabe, H.; Satake, A.; Yamamoto, A.; Omi, T.; Hiramoto, A.; Masutani, M.; Wataya, Y.; Kim, H. S. Role of Activating Transcription Factor 3 Protein ATF3 in Necrosis and Apoptosis Induced by 5-Fluoro-2’-Deoxyuridine. FEBS J. 2014, 281, 1892–1900. DOI: 10.1111/febs.12752.
   PubMed Web of Science ®Google Scholar
• Kurasaka, C.; Nishizawa, N.; Ogino, Y.; Sato, A. Trapping of 5-Fluorodeoxyuridine Monophosphate by Thymidylate Synthase Confers Resistance to 5-Fluorouracil. ACS Omega. 2022, 7, 6046–6052. DOI: 10.1021/acsomega.1c06394.
   PubMed Web of Science ®Google Scholar
• Inada, M.; Sato, A.; Shindo, M.; Yamamoto, Y.; Akasaki, Y.; Ichimura, K.; Tanuma, S. I. Anticancer Non-Narcotic Opium Alkaloid Papaverine Suppresses Human Glioblastoma Cell Growth. Anticancer Res. 2019, 39, 6743–6750. DOI: 10.21873/anticanres.13889.
   PubMed Web of Science ®Google Scholar
• Chen, C.; Shu, L.; Zou, W. Role of Long Non-Coding RNA TP73-AS1 in Cancer. Biosci Rep. 2019, 39, BSR20192274.
   PubMed Web of Science ®Google Scholar
• Pang, J. C.; Li, K. K.; Lau, K. M.; Ng, Y. L.; Wong, J.; Chung, N. Y.; Li, H. M.; Chui, Y. L.; Lui, V. W.; Chen, Z. P.; et al. KIAA0495/PDAM is Frequently Downregulated in Oligodendroglial Tumors and Its Knockdown by siRNA Induces Cisplatin Resistance in Glioma Cells. Brain Pathol. 2010, 20, 1021–1032. DOI: 10.1111/j.1750-3639.2010.00405.x.
   PubMed Web of Science ®Google Scholar
• Xiao, S.; Wang, R.; Wu, X.; Liu, W.; Ma, S. The Long Noncoding RNA TP73-AS1 Interacted with miR-124 to Modulate Glioma Growth by Targeting Inhibitor of Apoptosis-Stimulating Protein of p53. DNA Cell Biol. 2018, 37, 117–125. DOI: 10.1089/dna.2017.3941.
   PubMed Web of Science ®Google Scholar
• Zhang, R.; Jin, H.; Lou, F. The Long Non-Coding RNA TP73-AS1 Interacted with miR-142 to Modulate Brain Glioma Growth through HMGB1/RAGE Pathway. J. Cell. Biochem. 2018, 119, 3007–3016. DOI: 10.1002/jcb.26021.
   PubMed Web of Science ®Google Scholar
• Mazor, G.; Levin, L.; Picard, D.; Ahmadov, U.; Carén, H.; Borkhardt, A.; Reifenberger, G.; Leprivier, G.; Remke, M.; Rotblat, B. The lncRNA TP73-AS1 is Linked to Aggressiveness in Glioblastoma and Promotes Temozolomide Resistance in Glioblastoma Cancer Stem Cells. Cell Death Dis. 2019, 10, 246. DOI: 10.1038/s41419-019-1477-5.
   PubMed Web of Science ®Google Scholar